Integra LifeSciences price target lowered to $49 from $55 at JMP Securities

JMP Securities lowered the firm’s price target on Integra LifeSciences to $49 from $55 and keeps an Outperform rating on the shares. The impact of the Boston facility being offline was evident in the Q4 results, as were some temporary throughput issues with Integra skin at one manufacturing line, with the latter already being largely addressed, the analyst tells investors in a research note. Initial 2024 guidance includes these headwinds, but also with them moderating and eventually clearing as the year progresses, the firm adds.